The purpose of this study was to investigate the potential roles of the SH3-containing guanine nucleotide exchange factor (SGEF) in human prostate cancer.
Experimental data showed that SGEF was overexpressed in human prostate cancer cells and specimens. The reduction of SGEF expression through an SGEF-targeting siRNA in androgen-independent C4-2 and C4-2B cells suppressed both anchorage-dependent and anchorage-independent growth. In addition, the androgen receptor (AR) antagonist bicalutamide further strengthened this inhibitory effect due to the suppression of the elevated AR transactivation after knockdown of SGEF. Collectively, our results provide the first demonstration that SGEF is a novel promoter of human prostate cancer progression and development.
Written by:
Wang H, Wu R, Yu L, Wu F, Li S, Zhao Y, Li H, Luo G, Wang J, Zhou J. Are you the author?
Laboratory of Medical Molecular Biology, Beijing Institute of Biotechnology, Beijing, P.R. China.
Reference: Oncol Rep. 2012 Oct;28(4):1468-74.
doi: 10.3892/or.2012.1917
PubMed Abstract
PMID: 22824926
UroToday.com Investigative Urology Section
